Europska Unija - hrvatski - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - guanfacin hidroklorid - deficit poremećaja pozornosti s hiperaktivnošću - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv bi trebao biti korišten kao dio integriranog programa za liječenje adhd-om, kao i obično, uključujući psihološke, obrazovne i socijalne mjere.

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

le vet. beheer bv, wilgenweg 7, 3421 tv oudewater, nizozemska - levotiroksinnatrij - tableta za pse i mačke - pasa, mačaka

Europska Unija - hrvatski - EMA (European Medicines Agency)

eli lilly nederland b.v. - inzulin glargin - Šećerna bolest - lijekovi koji se koriste u dijabetesu - liječenje dijabetes melitusa kod odraslih, adolescenata i djece u dobi od 2 godine i više.

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

novartis ba d.o.o. - rasagilin - tableta - 1 mg/1 tableta - 1 tableta sadrži: 1 mg rasagilina (u obliku rasagilin tartarata)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

novartis ba d.o.o. - rasagilin - tableta - 1 mg/1 tableta - 1 tableta sadrži: 1 mg rasagilina (u obliku rasagilin tartarata)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

krka farma d.o.o. sarajevo - rasagilin - tableta - 1 mg/1 tableta - 1 tableta sadrži: 1mg rasagilina (u obliku rasagilin hemitartarata)

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - drugi antineoplastični agensi - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

nova laboratories ireland limited - 6-merkaptopurin monohidrat - leukemija, limfoid - antineoplastična sredstva - xaluprin je indiciran za liječenje akutne limfoblastične leukemije (all) u odraslih, adolescenata i djece.

Europska Unija - hrvatski - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolakton - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 i 5.